Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of traditional Chinese medicine composition and its application for treating myelodysplastic syndrome

A technology for myelodysplasia and syndrome, which can be used in drug combinations, pharmaceutical formulations, plant raw materials, etc., can solve the problems of expensive treatment costs, higher than leukemia, and high transplant-related risks, and achieve the effect of broadening the scope of drug selection.

Active Publication Date: 2016-02-03
浙江中医药大学附属第一医院
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Among them, the low-risk group is treated with cytokine combined supportive therapy, and the focus of treatment is to improve hematological abnormalities. The middle-risk group and high-risk group often have multilineage hematopoiesis and malignant clonal hyperplasia at the same time. The goal of treatment is to reduce the risk of leukemia transformation. To improve the prognosis, the treatment is mainly chemotherapy combined with cytokine therapy, the curative effect is worse than that of acute myeloid leukemia (AML), and allogeneic hematopoietic stem cell transplantation can have a better effect, but the risk related to transplantation is significantly higher than that of leukemia (GreenbergP. L..Current therapeutic approaches for patients with myelodysplasticsyndromes. BrJ Haematol, 2010, 150(2):131-43. Comparisonofidarubicin+ara-C-, fludarabine+ara-C-, andtopotecan+ara-C-based regimensintreatmentofnewlydiagnosedacutemyeloidleukemia, refractoryanemiawithexcessblastsintransformation, orrefractoryanemiawithexcessblasts. Blood, 2001, 98(13):3575-83.)
However, since most patients are elderly and cannot tolerate bone marrow transplantation, and the risks associated with transplantation are high, most patients have to rely on drug treatment and blood transfusion to survive, and eventually transform into AML and die. Primary AML is an abnormality in the bone marrow. Blast cells (leukemic cells) proliferate in large numbers and infiltrate various organs and tissues, so that normal hematopoiesis is inhibited. The remission rate of conventional chemotherapy is 55-72%. The characteristics are very different, insensitive to chemotherapy, prone to drug resistance, and poor prognosis
In recent years, the demethylation drugs 5-aza-cytidine (5-aza-cytidine, AzaC) and 5-aza-2'-deoxycytidine (5-aza-2'-deoxycytidine (5-aza-2 '-deoxycitidine, DAC), due to non-targeted cytotoxicity, potential carcinogenicity, emergence of drug-resistant cases after clinical application, and expensive treatment costs, limit its therapeutic application in MDS (QinT., CastoroR., EIAhdabS ., et al.Mechanismsof resistancetodecitabineinthemyelodysplasticsyndrome.PLoSOne, 2011, 6(8):e23372)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of traditional Chinese medicine composition and its application for treating myelodysplastic syndrome
  • A kind of traditional Chinese medicine composition and its application for treating myelodysplastic syndrome
  • A kind of traditional Chinese medicine composition and its application for treating myelodysplastic syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] 1Kg dry coarse powder of C. chinensis, heated and refluxed with 12000mL of 80% ethanol for 3 times, 2h each time, combined the extracts, concentrated under reduced pressure to obtain 100g thick extract. Add 500mL of water to form a suspension, and extract three times with 500mL of petroleum ether, 500mL of chloroform, and 500mL of n-butanol. Take the n-butanol extract, recover it to dryness under reduced pressure, and obtain the n-butanol fraction (40g), mix the sample with thick silica gel (800g), load the sample on a silica gel (100-200 mesh) column, and wash with chloroform-methanol (80 :20) elution, the resulting fraction is recovered to dryness under reduced pressure to obtain component a11g.

[0031] Eucommia ulmoides leaves 1kg dry coarse powder, heated and refluxed with 10000mL of 80% ethanol for 3 times, 2h each time, combined extracts, concentrated under reduced pressure to obtain 130g of thick extract. Add 500mL water to form a suspension, and extract three ...

Embodiment 2

[0034] Embodiment 2: The application of Chinese medicine composition effective component (PHDE) to myelodysplastic syndrome suppression

[0035] (1) Cell culture

[0036] The human MDS cell line Skm-1 cell line was donated by the Institute of Blood Diseases of the First Affiliated Hospital of Zhejiang University School of Medicine. The cell line was established from a high-risk MDS patient by Japanese scholar Nakagawa. The cell culture conditions were 10% GIBCO Fetal Bovine Serum RPMI1640 complete medium at 37°C, 5% CO 2 cultured in an incubator and subcultured once a day.

[0037] (2) MTT method to detect cell viability

[0038] Take Skm-1 cells in the logarithmic growth phase and suspend them in RPMI1640 medium. After counting, count them according to 5×10 4 cells / mL were implanted into 24-well culture plates, 1 mL per well. In the experiment, a drug-dosing group and a control group were set up: the drug-dosing groups had drug concentrations of 0.05, 0.075, 0.1, and 0.12...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a traditional Chinese medicine composition for treating myelodysplastic syndrome and applications thereof. The traditional Chinese medicine is composed of the following raw materials in parts by weight: 10 to 50 parts of lygodium japonicum, 10 to 50 parts of eucommia leaf, and 40 to 90 parts of oldenlandia diffusa. A new drug for treating myelodysplastic syndrome is added into the drug list, the drug choosing range for patients is enlarged, and a new candidate drug is developed for treating myelodysplastic syndrome.

Description

(1) Technical field [0001] The invention relates to a traditional Chinese medicine composition for treating myelodysplastic syndrome and its application. (2) Background technology [0002] Myelodysplastic syndromes (myelodysplastic syndromes, MDS) are a group of malignant clonal stem cell diseases characterized by ineffective hematopoiesis in the bone marrow and reduction of one, two or multiple lines of peripheral blood cells, and have a high risk of transformation to acute leukemia. Up to 3.3 / 100,000 (CogleC.R., CraigB.M., RollisonD.E., et al.Incidenceofthemyelodysplasticsyndromesusingnovelclaims-basedalgorithm:highnumberofuncapturedcasesbycancerregistries[J].Blood, 2011,117(26):7121-5.). Currently newly diagnosed high-risk MDS has an upward trend (SekeresM.A., SchoonenW.M., KantarjianH., etal.CharacteristicsofUS Patientwithmyelodysplasticsyndromes:resultsofsixcross-sectionalphysiciansurveys[J].JNatlCancerInst, 2008,100(21):1542-51.), The only curative option is allogenei...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/748A61P7/00A61P7/06
Inventor 林圣云蒋剑平叶宝东李静
Owner 浙江中医药大学附属第一医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com